PMID,PMCID,Comment,Title,Study Parameters Count,Drug Annotations Count,Functional Analysis Annotations Count,Phenotype Annotations Count
39346054,PMC11430164,"in vitro study CYP3A4, lots of variants",,0,0,2,0
38216550,PMC10786722,DPYD,Integrating rare genetic variants into DPYD pharmacogenetic testing may help preventing fluoropyrimidine-induced toxicity,3,0,3,0
38568509,PMC10993165,"drug combination (sulfamethoxazole / trimethoprim), HLA, scar",Human Leukocyte Antigens and Sulfamethoxazole/Cotrimoxazole–Induced Severe Cutaneous Adverse Reactions: A Systematic Review and Meta-Analysis,5,0,0,3
40786508,PMC12331468,"DPYD, TYMS and others, bunch of cancer chemotherapy toxicities",,6,0,0,5
40761554,PMC12319246,tacrolimus kidney transplant lots of VAs,,8,0,0,8
40672687,PMC12260932,mix of PK and complex efficacy,,3,3,0,0
37332933,PMC10275785,responders/non-responders rheumatoid arthritis,Effect of NLRP3 inflammasome genes polymorphism on disease susceptibility and response to TNF-α inhibitors in Iraqi patients with rheumatoid arthritis,2,2,0,0
40762011,PMC12320098,content to suitable for VA,,0,0,0,0
28550460,PMC5508045,warfarin,The impact of non-genetic and genetic factors on a stable warfarin dose in Thai patients,4,4,0,0
26745506,PMC4706412,warfarin,A Novel Admixture-Based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics,7,4,0,0
39604537,PMC11603346,CYP2B6/efavirenz,Association between the CYP2B6 polymorphisms and nonnucleoside reverse transcriptase inhibitors drug-induced liver injury: a systematic review and meta-analysis,2,0,0,2
20338069,PMC2859392,CYP2B6/efavirenz,Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults,2,2,0,0
37490620,PMC10399933,statins,"Real-world pharmacogenetics of statin intolerance: effects of SLCO1B1, ABCG2, and CYP2C9 variants",10,0,0,5
40297930,PMC12038368,simvastatin,,2,2,0,0
26715213,PMC4916189,efavirenz,"Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study",7,0,0,7
30336686,PMC6714829,simvastatin,"Associations of the SLCO1B1 Polymorphisms With Hepatic Function, Baseline Lipid Levels, and Lipid-lowering Response to Simvastatin in Patients With Hyperlipidemia",2,2,0,0
38497131,PMC10946077,UGT1A1,Individual Irinotecan Therapy Under the Guidance of Pre-Treated UGT1A1*6 Genotyping in Gastric Cancer,7,0,0,3
38707740,PMC11062152,UGT1A1,Risk Factors for Adverse Events of Nanoliposomal Irinotecan Plus 5-Fluorouracil and L-leucovorin,3,0,0,2
31024313,PMC6465603,TPMT/NUDT15,NUDT15 Polymorphism Confer Increased Susceptibility to Thiopurine-Induced Leukopenia in Patients With Autoimmune Hepatitis and Related Cirrhosis,2,0,0,2
35431360,PMC8973308,TPMT/NUDT15,Susceptibility to thiopurine toxicity by TPMT and NUDT15 variants in Colombian children with acute lymphoblastic leukemia,3,2,0,1
40099566,PMC12035587,NUDT15,Severe myelosuppression and alopecia after thiopurine initiation in a patient with NUDT15 deficiency,1,0,0,1
28819312,PMC5561238,HLAs,Shared peptide binding of HLA Class I and II alleles associate with cutaneous nevirapine hypersensitivity and identify novel risk alleles,43,0,0,43
23588310,PMC3839910,HLAs,HLA-A*31:01 and HLA-B*15:02 as genetic markers for carbamazepine hypersensitivity in children,6,0,0,6
15024131,PMC384715,HLAs,Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant,2,0,0,1
21428769,PMC3113609,HLAs,HLA-A★3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans,3,0,0,3
15743917,PMC554812,HLAs,HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol,14,0,0,5
21505298,PMC3387531,HLAs,"Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent",6,0,0,6
33768542,PMC8790808,HLAs,Class II HLA Variants Associate with Risk of Pegaspargase Hypersensitivity,8,0,0,4
15590749,none,"CYP2D6/CYP2C19-toxicity, response, PK (not in pubmed central) but really good example of complexity",,0,0,0,0
23213055,PMC3548984,CYP2D6/tamoxifen/response,CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8,3,0,0,3
23476897,PMC3584248,CYP2D6/tamoxifen/concentration; response is reported for endoxifen concentration so we cannot capture,"CYP2D6 genotypes, endoxifen levels, and disease recurrence in 224 Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancer",4,2,0,0
30661084,PMC6435416,CYP2D6 risperidone toxicity - strong 2d6 inhibitors mentioned but phenoconversion not considered in analysis,CYP2D6 genotype and adverse events to risperidone in children and adolescents,1,0,0,1
40184070,PMC11971672,CYP2C19/clopidogrel,,2,0,0,1
40295977,PMC12036300,CYP2C19/clopidogrel,,2,0,0,2
38377518,PMC10880264,CYP2D6/CYP2C19 - escitalopram toxicity,Pharmacogenetic Factors Influence Escitalopram Pharmacokinetics and Adverse Events in Youth with a Family History of Bipolar Disorder: A Preliminary Study,4,1,0,3
